Ketamine as a fast acting antidepressant: current knowledge and open questions

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Ketamine, an NMDA receptor antagonist, demonstrates rapid antidepressant effects in treatment-resistant mood disorders.
• It also shows efficacy in reducing suicidal ideation, sparking significant research interest.

Purpose of the Study:

• To review clinical evidence on ketamine for mood disorders.
• To explore preclinical and human studies on ketamine's mechanisms of action and response predictors.
• To identify knowledge gaps and suggest future research directions.

Main Methods:

• Literature review of clinical studies on ketamine in mood disorders.
• Analysis of preclinical and human research investigating ketamine's mechanisms.
• Examination of biomarkers for antidepressant response.

Main Results:

• Emerging evidence suggests ketamine's antidepressant properties involve increased AMPA signaling and synaptogenesis.
• Pilot clinical studies are promising but raise questions about optimal dosing and administration.
• Biomarkers for response prediction remain largely unidentified.

Conclusions:

• Ketamine offers a promising avenue for developing novel, fast-acting antidepressants.
• Further research is critical to address safety, efficacy, and personalized treatment strategies.
• Understanding ketamine's mechanisms and identifying response predictors are key future directions.